Skip to main content
. 2012 Feb 28;6(2):e1536. doi: 10.1371/journal.pntd.0001536

Figure 2. Infection-enhancement activity in serum samples with neutralizing activity to DENV-2.

Figure 2

Six serum samples with high neutralizing activity to DENV-2 at 1∶10 serum dilutions were tested for presence of infection-enhancement activity to DENV-2 at serum dilutions of 1∶10 to 1∶106. (A) serum sample #40, (B) #42, (C) #44 (D) #49, (E) #54 and, (F) #58. Infection-enhancement activity to each DENV serotype was determined by using FcγR-expressing BHK cells and BHK cells by the formula: (mean plaque count at each serum dilution)/(mean plaque count in the absence of human serum samples), and expressed as fold enhancement to DENV-2. Closed bars indicate FcγR-expressing BHK cells and open bars indicate FcγR-negative BHK cells.